Axovant Sciences Ltd. (AXON) Given a $35.00 Price Target by HC Wainwright Analysts
Axovant Sciences Ltd. (NYSE:AXON) has been given a $35.00 target price by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 189.50% from the stock’s previous close.
A number of other analysts also recently issued reports on AXON. Piper Jaffray Companies set a $32.00 price objective on Axovant Sciences and gave the stock a “buy” rating in a research report on Sunday, December 18th. Oppenheimer Holdings, Inc. set a $20.00 target price on Axovant Sciences and gave the company a “buy” rating in a report on Sunday, December 25th. Robert W. Baird restated a “positive” rating and set a $29.00 target price on shares of Axovant Sciences in a report on Tuesday, December 20th. Cowen and Company assumed coverage on Axovant Sciences in a report on Tuesday. They set an “outperform” rating for the company. Finally, Zacks Investment Research cut Axovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, February 7th. Two equities research analysts have rated the stock with a sell rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $25.32.
Shares of Axovant Sciences (NYSE:AXON) traded up 2.63% during trading on Tuesday, reaching $12.09. 908,232 shares of the company’s stock were exchanged. The company’s market capitalization is $1.20 billion. The stock has a 50-day moving average price of $12.52 and a 200 day moving average price of $13.84. Axovant Sciences has a 12-month low of $9.92 and a 12-month high of $17.66.
Axovant Sciences (NYSE:AXON) last issued its quarterly earnings data on Tuesday, February 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.03. Equities analysts expect that Axovant Sciences will post ($1.65) EPS for the current fiscal year.
“Axovant Sciences Ltd. (AXON) Given a $35.00 Price Target by HC Wainwright Analysts” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of international trademark & copyright laws. The original version of this report can be accessed at http://www.watchlistnews.com/axovant-sciences-ltd-axon-given-a-35-00-price-target-by-hc-wainwright-analysts/1121041.html.
Several institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN boosted its position in shares of Axovant Sciences by 1.5% in the third quarter. Wells Fargo & Company MN now owns 8,130 shares of the company’s stock valued at $113,000 after buying an additional 117 shares during the last quarter. Princeton Capital Management Inc. bought a new position in shares of Axovant Sciences during the third quarter valued at about $145,000. Royal Bank of Canada boosted its position in shares of Axovant Sciences by 467.6% in the second quarter. Royal Bank of Canada now owns 10,500 shares of the company’s stock valued at $135,000 after buying an additional 8,650 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Axovant Sciences during the fourth quarter valued at about $139,000. Finally, Opus Point Partners Management LLC boosted its position in shares of Axovant Sciences by 10.9% in the third quarter. Opus Point Partners Management LLC now owns 14,844 shares of the company’s stock valued at $208,000 after buying an additional 1,455 shares during the last quarter.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a Bermuda-based clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.